Sign in
CompletedNo phase

Combined Treatment for Non-Healing Wounds in Chronic Lower Extremity Arterial Disease: A Comparative Study

Key facts

Who runs it
Tulip Medicine
Where
Kazakhstan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
116 people enrolled
Started
9 Jan 2023
Ended
6 Sept 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • balloon angioplasty and stenting of lower extremity vessels + fibroblasts
  • balloon angioplasty and stenting of lower extremity vessels
Record updated
1 October 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Male and female patients aged 18 to 75 years inclusive
  • Patients with a history of confirmed stable intermittent lameness, the symptoms of which have been observed continuously for at least 3 months at the time of randomization
  • Patients with a diagnosis of PAD (code I 70.2 - I 70.9 according to the International Classification of Diseases, 10th revision [ICD - 10]), confirmed by the results of ultrasound duplex scanning of blood vessels
  • Patients whose smoking status remained stable for at least 3 months prior to randomization (for smokers)
  • Patients with an ankle - brachial Doppler index value at rest ≤0.9
  • Patients with a long-term non-healing wound (more than 1 month) and intermittent claudication with a pain-free walking distance of less than 200 meters
  • Patients who, in the opinion of the investigator, are able to understand and comply with the study requirements
  • Before starting any examination procedures by the patient or, if applicable, its legal representative, a signed and dated written informed consent form, as well as any necessary processing permissions personal data

Who cannot take part

  • Patients who underwent reconstructive intervention on the arteries of the lower extremities (surgical or intravascular) in the last 3 months before randomization
  • Patients who underwent major cardiac surgery within 6 months prior to randomization
  • Progression of the underlying and concomitant disease
  • Acute myocardial infarction (ACS), acute cerebrovascular accident (stroke)
  • Acute infectious diseases
  • Patients with congestive heart failure III-IV functional class according to classification of the New York Heart Association
  • Patients with any other disease that significantly limits physical activity, or any other medical condition that, in the opinion of the investigator, may limit the patient's participation in the study
  • Patients with mental status disorders
  • Patients with a history of hypersensitivity or allergy to a radiopaque substance, similar drugs or excipients
  • Presence of peptic ulcer of the stomach and duodenum (DUD)
  • Patients with total thrombosis of the vessels of the lower extremities
  • High levels of creatinine and urea in a biochemical blood test (creatinine in women: more than 80.0 µmol / l; men: more than 110.0 µmol / l; ); ( Urea in adults under 60 years of age is more than 8.32 mmol/l, adults over 60 years of age are more than 7.5 mmol/l )
  • Pulmonary embolism (PE)
  • Patients who are pregnant or breastfeeding, or who plan to become pregnant before participating in this study or during the study, or who intend to become an egg donor within the same period of time

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Endovascular interventions, such as balloon angioplasty and stenting, are commonly used for PAD due to their proven safety and effectiveness. However, traditional treatments for chronic non-healing wounds are often insufficient. Advances in cell biotechnology, particularly fibroblast therapy, show promise for enhancing wound healing, as fibroblasts play a crucial role in tissue repair and inflammation.

Read full original descriptionShow less

This study aims to develop, assess, and evaluate the safety of a combined treatment approach that incorporates fibroblast therapy with existing methods for managing chronic non-healing wounds in PAD patients.

The 2 groups in the trial

  • combined treatmentTreatment being tested

    Combined treatment (balloon angioplasty or stenting + fibroblast transplantation).

    Treatment: balloon angioplasty and stenting of lower extremity vessels + fibroblasts

  • Endovascular treatmentExisting treatment, for comparison

    Endovascular interventions + traditional debridement.

    Treatment: balloon angioplasty and stenting of lower extremity vessels

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effectiveness of Combined Treatment Methods for Non-Healing Wounds in Patients With Chronic Lower Extremity Arterial Disease: A Comparative Study
Record updated
1 October 2026